Last updated: February 14, 2026
Overview of the Drug
NDC 31722-0962 identifies Tucidinostat (also known as XD105), an oral histone deacetylase (HDAC) inhibitor developed for oncology indications, primarily used in certain lymphomas and other hematological malignancies. It is marketed in China and other markets under various brand names, notably under Hainan Zhonghe Pharmaceutical Co., Ltd..
Market Landscape
Global Presence:
Tucidinostat has gained approval and market presence mainly in China, with limited exposure in the U.S. and Europe. Elsewhere, its adoption hinges on regulatory approvals and clinical development progress.
Market Size & Growth Drivers:
- The global lymphoma market was valued at approximately $3.5 billion in 2022; projected growth rate at 8% CAGR through 2027.[1]
- Tucidinostat targets specific subpopulations, including relapsed or refractory peripheral T-cell lymphoma (PTCL).
- The FDA has not yet approved Tucidinostat in the U.S.; China remains the primary market.[2]
Competitive Landscape:
Key competitors include other HDAC inhibitors like Vorinostat, Belinostat, and Chidamide.
| Drug |
Approved Indications |
Market Status |
Price Range (per 30-day supply) |
Notes |
| Vorinostat |
Cutaneous T-cell lymphoma (CLL) |
Approved in US, global markets |
$4,500–$6,000 |
Widely used; generic options |
| Belinostat |
PTCL, peripheral T-cell lymphoma |
Approved in US, EU, China |
$6,000–$8,000 |
Higher cost, niche market |
| Chidamide |
PTCL, other lymphomas |
Approved in China, India |
$2,000–$3,500 |
Growing in Asian markets |
| Tucidinostat |
PTCL, lymphoma |
Approved in China, some global markets |
$2,500–$4,000 |
Emerging in international markets, dependent on regulatory pathways |
Patent and Regulatory Considerations:
- The patent estate in China extends until at least 2028, with ongoing patent filings globally.
- U.S. and Europe are awaiting regulatory submissions; the required clinical data submission and approval timelines influence market entry.
Price Projection Models
Factors Affecting Price:
- Market penetration rate considering unmet need.
- Competition with existing treatments and generics.
- Regulatory approvals and reimbursement landscape.
- Manufacturing costs and supply chain factors.
Assumptions for Projections:
- Entry into the U.S. and Europe occurs by 2025–2026.
- Market share of 10–15% in the lymphoma segment within five years of launch.
- Per-unit pricing aligns with or is slightly below standard HDAC inhibitors due to regional negotiations and competitive pressures.
| Year |
Estimated Market Penetration |
Average Annual Price (per 30-day supply) |
Notes |
| 2023 |
0% (pre-market) |
N/A |
Regulatory approval pending |
| 2024 |
0% (pre-market) |
N/A |
Expected approval in China |
| 2025 |
5%–8% |
$2,800–$3,500 |
Launch in China, initial markets |
| 2026 |
8%–12% |
$2,700–$3,400 |
Launch in U.S., EU if approved |
| 2027 |
10%–15% |
$2,600–$3,200 |
Market expansion |
| 2030 |
15%–20% |
$2,500–$3,000 |
Saturation point |
Price erosion due to increased competition and generic entry could lower prices by 10–15% annually post-2027.
Revenue Potential
Estimating US$50–100 million at peak sales in targeted markets by 2030, assuming successful regulatory approval and competitive situating. Chinese sales could represent a larger share due to broader approval, with revenues possibly exceeding US$150 million annually by 2030.
Risks and Challenges
- Delays in regulatory approval outside China.
- Patent cliffs once exclusivity ends.
- Competition from generic HDAC inhibitors.
- Clinical success rate impact due to potential toxicity or lack of broad efficacy data.
Key Takeaways
- Tucidinostat's primary market is China, where it has established regulatory approval; expansion depends on approvals elsewhere, especially the U.S. and EU.
- Market entry could occur by 2025–2026; pricing likely to be in the $2,500–$3,500 range, similar to existing HDAC inhibitors.
- Peak revenues worldwide could reach near US$200 million, with greatest growth driven by domestic Chinese sales and expanded indications.
- Competitive pressure will influence pricing and market share, especially post-patent expiration.
FAQs
Q1: When is Tucidinostat expected to be approved in the U.S.?
A1: Regulatory approval is anticipated between 2024 and 2026, contingent on submission of additional clinical data and FDA review timelines.
Q2: What are the key competitors of Tucidinostat in the market?
A2: Vorinostat, Belinostat, and Chidamide are primary competitors, with Vorinostat having broader global approval and Chidamide being more prevalent in Asian markets.
Q3: How does the price of Tucidinostat compare to other HDAC inhibitors?
A3: It is comparable, with an estimated $2,500–$3,500 per 30-day supply, slightly lower than Belinostat and Vorinostat, depending on regional negotiations.
Q4: What are the main factors influencing Tucidinostat’s market success?
A4: Regulatory approval outside China, clinical efficacy, safety profile, pricing, and competitive positioning will determine market success.
Q5: What is the impact of patent expirations on Tucidinostat’s pricing?
A5: Patent expirations in key markets will likely lead to generic entry and price declines of 10–15% annually post-expiry.
References
- Grand View Research, "Lymphoma Market Size & Trends," 2022.
- Chinese National Medical Products Administration, "Drug Approvals," 2022.
